Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

被引：0
|
作者：
Michela Del Prete
François-Alexandre Buteau
Jean-Mathieu Beauregard
机构：
[1] Université Laval,Department of Radiology and Nuclear Medicine, and Cancer Research Center
[2] CHU de Québec – Université Laval,Department of Medical Imaging, and Oncology Branch of Research Center
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Personalized; Peptide receptor radionuclide therapy; Lu-octreotate; Dosimetry; Neuroendocrine tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1490 / 1500
页数：10
相关论文
共 50 条
  • [31] Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy
    Ransom, D.
    Kennedy, K.
    Turner, J.
    Macdonald, W.
    Boardman, G.
    Claringbold, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 205 - 205
  • [32] Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
    Amir Sabet
    Torjan Haslerud
    Ulrich-Frank Pape
    Amin Sabet
    Hojjat Ahmadzadehfar
    Frank Grünwald
    Stefan Guhlke
    Hans-Jürgen Biersack
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 205 - 210
  • [33] Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
    Ezziddin, Samer
    Sabet, Amir
    Heinemann, Florian
    Yong-Hing, Charlotte J.
    Ahmadzadehfar, Hojjat
    Guhlke, Stefan
    Hoeller, Tobias
    Willinek, Winfried
    Boy, Christian
    Biersack, Hans-Juergen
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (08) : 1197 - 1203
  • [34] Salvage therapy with 177Lu-octreotate in patients with gastroenteropancreatic neuroendocrine tumors
    Van Essen, Martijn
    Krenning, Eric
    Kam, Boen
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [35] Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours
    Yordanova, A.
    Wicharz, M.
    Gonzalez-Carmona, M.
    Strassburg, C.
    Mayer, K.
    Brossart, P.
    Essler, M.
    Ahmadzadehfar, H.
    NEUROENDOCRINOLOGY, 2017, 105 : 258 - 258
  • [36] Outcome of peptide receptor radionuclide therapy with 177-Lu-octreotate in advanced neuroendocrine tumours (NET): South Australian sub study of the SIGNETURe Registry
    Patel, D.
    Lawrie, J.
    Cehic, G.
    Kitchener, M.
    Unger, S.
    Singhal, N.
    Karapetis, C.
    Michael, M.
    Kotasek, D.
    Chua, Y. J.
    Price, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S413 - S413
  • [37] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [38] Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate
    Ezziddin, S.
    Sabet, A.
    Heinemann, F.
    Yong-Hing, C.
    Ahmadzadehfar, H.
    Guhlke, S.
    Hoeller, T.
    Willinek, W.
    Boy, C.
    Biersack, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [39] RADIOPEPTIDE CONTROL OF ENDOCRINE CANCER: A PHASE IIA STUDY OF 177LU-OCTREOTATE/CAPECITABINE THERAPY OF DISSEMINATED NEUROENDOCRINE TUMOURS
    Claringbold, P. G.
    Brayshaw, P. A.
    Krenning, E. P.
    Kwekkeboom, D. J.
    Turner, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 167 - 168
  • [40] The Tumour Sink Effect on Renal Dosimetry in Patients Treated with 177Lu-Octreotate for Neuroendocrine Tumour: A Potential Role of 68Ga-octreotate-PET/CT for Planning Personalized Peptide Receptor Radionuclide Therapy
    Beauregard, J. M.
    Hofman, M. S.
    Jackson, P.
    Kong, G.
    Hicks, R. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S282 - S283
12345